Curi RMB Capital LLC Sells 17,964 Shares of Pfizer Inc. (NYSE:PFE)

Curi RMB Capital LLC reduced its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 32.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,806 shares of the biopharmaceutical company's stock after selling 17,964 shares during the period. Curi RMB Capital LLC's holdings in Pfizer were worth $1,003,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Retirement Wealth Solutions LLC acquired a new stake in Pfizer during the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer in the fourth quarter valued at $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer during the 4th quarter worth about $28,000. Noble Wealth Management PBC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $31,000. Finally, Curio Wealth LLC acquired a new position in shares of Pfizer in the fourth quarter worth approximately $32,000. Institutional investors own 68.36% of the company's stock.

Insider Activity

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.06% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on PFE shares. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group decreased their price target on Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a report on Tuesday, April 8th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $31.07.

Pfizer Stock Down 0.3 %

NYSE:PFE traded down $0.07 during trading hours on Monday, hitting $22.07. 31,814,050 shares of the company traded hands, compared to its average volume of 40,452,372. The firm's 50-day simple moving average is $24.81 and its 200-day simple moving average is $26.11. The company has a market cap of $125.17 billion, a PE ratio of 15.65, a PEG ratio of 0.64 and a beta of 0.67. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.10 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.